AavantiBio lands manufacturing partner in Friedreich's Ataxia program; NC Research Triangle lands another CDMO
AavantiBio and Resilience have announced a collaboration to manufacture a pipeline of therapies, including AavantiBio’s Friedreich’s Ataxia program, the company announced Thursday.
The adeno-associated viral vector-based candidate is currently in Phase I/II trials in the US and Europe, and Resilience will provide cell lines and viral banks for the drug’s first in-human trials. The drug will be manufactured at Resilience’s 183,000-square-foot facility in Alachua, FL.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.